NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»22/12/2009 [Company watch]
Alvogen Opens Office in China

Alvogen announced December 15 that the company has commenced Asia operations with the establishment of a corporate presence in Shanghai, the Medical News reported. The new subsidiary in China will source active pharmaceutical ingredients and finished products for the company\'s business units in North America, Europe and Asia, and will also serve as a springboard for business development efforts in the China and Asia markets.

 

Alvogen announced December 15 that the company has commenced Asia operations with the establishment of a corporate presence in Shanghai, the Medical News reported. The new subsidiary in China will source active pharmaceutical ingredients and finished products for the company\'s business units in North America, Europe and Asia, and will also serve as a springboard for business development efforts in the China and Asia markets.

Robert Wessman, Executive Chairman of Alvogen, suggested that the company will also strengthen development, manufacturing, and outsourcing capabilities by new collaborations in China. Qin Maximilian Lue, who is the major holder of Shanghai-based Mephax Holdings, was appointed as the managing director of Alvogen China and will lead the company\'s local team.

US-based Alvogen focuses on the development of "specialty generics" which may have advanced formulation or manufacturing requirements.

 

Astellas Wins Approval for Overactive Bladder Treatment in China


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.